To include your compound in the COVID-19 Resource Center, submit it here.

BrainStorm starts Ph III of NurOwn to treat ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) began a Phase III trial of NurOwn (MSC-NTF

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE